Snus: a compelling harm reduction alternative to cigarettes
Open Access
- 27 November 2019
- journal article
- review article
- Published by Springer Nature in Harm Reduction Journal
- Vol. 16 (1) , 1-17
Abstract
Snus is an oral smokeless tobacco product which is usually placed behind the upper lip, either in a loose form or in portioned sachets, and is primarily used in Sweden and Norway. The purpose of this review is to examine the reported effects of snus use in relation to specified health effects, namely lung cancer, cardiovascular disease, pancreatic cancer, diabetes, oral cancer and non-neoplastic oral disease. The review also examines the harm reduction potential of snus as an alternative to cigarettes by comparing the prevalence of snus use and cigarette smoking, and the reported incidence of tobacco-related diseases across European Union countries. The scientific literature generally indicates that the use of snus is not a significant risk factor for developing lung cancer, cardiovascular disease, pancreatic cancer or oral cancer. Studies investigating snus use and diabetes have reported that high consumption of snus (estimated as being four or more cans per week) may be associated with a higher risk of developing diabetes or components of metabolic syndrome; however, overall results are not conclusive. Snus use is associated with the presence of non-neoplastic oral mucosal lesions which are reported to heal rapidly once use has stopped. The most recent Eurobarometer data from 2017 reported that Sweden had the lowest prevalence of daily cigarette use in the European Union at 5% whilst daily “oral tobacco” use was reported to be 20%. European data published by the World Health Organisation in 2018 indicated that Sweden had the lowest rate of tobacco-related mortality and the lowest incidence of male lung cancer. Overall, prevalence statistics and epidemiological data indicate that the use of snus confers a significant harm reduction benefit which is reflected in the comparatively low levels of tobacco-related disease in Sweden when compared with the rest of Europe. The available scientific data, including long-term population studies conducted by independent bodies, demonstrates that the health risks associated with snus are considerably lower than those associated with cigarette smoking.Keywords
This publication has 91 references indexed in Scilit:
- Risk equations for the development of worsened glucose status and type 2 diabetes mellitus in a Swedish intervention programBMC Public Health, 2013
- The association between use of snus and quit rates for smoking: results from seven Norwegian cross-sectional studiesAddiction, 2010
- The relation between smokeless tobacco and cancer in Northern Europe and North America. A commentary on differences between the conclusions reached by two recent reviewsBMC Cancer, 2009
- Swedish snuff and incidence of cardiovascular disease. A population-based cohort studyBMC Cardiovascular Disorders, 2009
- Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North AmericaBMC Cancer, 2008
- Smokeless Tobacco and the Risk of StrokeEpidemiology, 2008
- Systematic review of the relation between smokeless tobacco and non-neoplastic oral diseases in Europe and the United StatesBMC Oral Health, 2008
- Switching to smokeless tobacco as a smoking cessation method: evidence from the 2000 National Health Interview SurveyHarm Reduction Journal, 2008
- Snus use and other correlates of smoking cessation in the Swedish Twin RegistryPsychological Medicine, 2007
- Smokeless tobacco use and risk of cancer of the pancreas and other organsInternational Journal of Cancer, 2005